Despite Medicare coverage, many cancer patients still do not receive testing that guides treatment options. While there has been a recent increase among Medicare recipients in genomic testing that helps match cancer patients to the most effective treatment for their tumor, many Medicare beneficiaries with cancer are still not receiving next-generation sequencing (NGS), according to a new analysis by Georgetown University researchers.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: While there has been a recent increase among Medicare recipients in genomic testing that helps match cancer patients to the most effective treatment for their tumor, many Medicare beneficiaries with cancer are still not receiving next-generation sequencing (NGS), according to a new analysis by Georgetown University researchers.
- Ponto de atenção: despite.
- Ponto de atenção: medicare.
- Ponto de atenção: coverage.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
Acompanhe a Recifes.net
Entre no Canal do WhatsApp da Recifes.net para receber noticias, bastidores e atualizacoes editoriais diretamente no WhatsApp.
